Lucentis vs Syfovre
Side-by-side cost comparison based on Medicare Part D data
Lucentis
Ranibizumab
Manufactured by Genentech/Roche
Syfovre
Pegcetacoplan
Manufactured by Apellis
Lucentis costs 64% less per claim than Syfovre ($654.00 vs $1,839.00). A generic version of Lucentis is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Lucentis | Syfovre |
|---|---|---|
| Avg Cost Per Claim | $654.00 | $1,839.00 |
| Total Medicare Spending | $1.1B | $456.0M |
| Total Beneficiaries | 245,000 | 32,000 |
| Total Claims | 1,680,000 | 248,000 |
| Annual Cost/Patient | $4,482.00 | $14,250.00 |
| Year-over-Year Change | -22.3% | 0.0% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Genentech/Roche | Apellis |
| Condition | Eye Diseases | Eye Diseases |
| Generic Name | Ranibizumab | Pegcetacoplan |
Lucentis vs Syfovre: What the Data Shows
Lucentis (Ranibizumab) and Syfovre (Pegcetacoplan) are both used to treat eye diseases. Based on Medicare Part D data, Lucentis costs $654.00 per claim, which is 64% less than Syfovre at $1,839.00 per claim.
Medicare spent $1.1B on Lucentis and $456.0M on Syfovre. In terms of patient reach, Lucentis serves more beneficiaries (245,000 vs 32,000).
Year-over-year spending changed -22.3% for Lucentis and 0.0% for Syfovre.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Lucentis is cheaper at $654.00 per claim, compared to $1,839.00 for Syfovre. That makes Lucentis about 64% less expensive per claim based on Medicare Part D data.
Yes, both Lucentis and Syfovre are used to treat eye diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Ranibizumab and generic Pegcetacoplan can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $1.1B on Lucentis covering 245,000 beneficiaries, and $456.0M on Syfovre covering 32,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.